Skip to content

Exploring the therapeutic potential of psychedelics in treating substance use disorders.

Yuanpeng Li, Hongyuan Li, Hongshuang Wang, Xiaohui Wang

Molecular Psychiatry December 1, 2025 DOI: 10.1038/s41380-025-03168-w (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Review Peer reviewed
Topics Addiction
Key findings Psilocybin-assisted therapy shows significant reductions in substance use and improved mental health outcomes across various substance use disorders.

Abstract

Psychedelics, particularly psilocybin, have garnered significant attention as potential therapeutic tools for treating substance use disorders (SUDs), such as those related to alcohol, nicotine, heroin (an opioid), or cocaine. Traditional treatments often fall short, leading to high relapse rates and an urgent need for innovative approaches. This article explores the emerging role of psychedelics in SUDs therapy, highlighting their ability to disrupt maladaptive neural circuits, promote neuroplasticity, and facilitate profound psychological insights that address the root causes of SUDs. Clinical trials demonstrate promising results across various forms of SUDs, with psilocybin-assisted therapy showing significant reductions in substance use and improved mental health outcomes. Despite the potential, challenges such as legal barriers, safety concerns, and the need for more rigorous research remain. The future of psychedelics in SUDs treatment is cautiously optimistic, with the possibility of transforming the field of SUDs therapy and offering hope to millions of individuals struggling with SUDs.